Objectives Inhibitors of the renin-angiotensin system are recommended for the management
of albuminuria in patients with hypertension and diabetes mellitus, but there is little …

Clinical practice guidelines recommend blockers of the renin-angiotensin system alone or in
combination with other agents to reduce blood pressure and albuminuria in patients with …

In the present study, we tested the hypothesis that up-titrating the dose of an angiotensin
receptor blocker (ARB) is superior to combined treatment with an ARB and a calcium …

Conventional risk factors associated with cardiovascular and renal complications of diabetes
include hypertension, dyslipidemia, hyperglycemia, and smoking. Recently, albuminuria has …

Diabetic nephropathy management should include the use of an angiotensin‐converting
enzyme inhibitor (ACEI) or an angiotensin receptor blocker with additional antihypertensive …

Objective: To review the use of nondihydropyridine calcium channel blockers (non-DHP
CCBs) for the treatment of proteinuria in diabetic and nondiabetic kidney disease. Data …

BACKGROUND It is unclear when angiotensin II receptor blockers (ARBs) produce their
strongest antialbuminuric effect (AAE) in patients with diabetic nephropathy. ARBs produce …

Background The multicenter double-blind, randomized Bergamo Nephrologic Diabetes
Complications Trial (BENEDICT) was designed to assess whether angiotensin-converting …

The combination of a calcium channel blocker (CCB) and a blocker of the renin–angiotensin–
aldosterone system (RAAS) is recommended in clinical practice guidelines. L/N-and L/T …

Background It has been suggested that renoprotection with calcium channel blockers
(CCBs) may differ. This study aimed to compare the anti‐proteinuric effect of different CCBs …